In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Steve Kanes, MD, PhD, Chief Medical Officer at SAGE Therapeutics about the SAGE 547 Trial in Status Epilepticus.
SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE). SAGE-547 demonstrated robust findings in preclinical models of SE, including significantly increased efficacy over current standard-of-care benzodiazepine treatment, and compelling early human experience data.
After the interview, you can learn more about refractory epilepsy at: http://www.epilepsy.com/learn/refractory-epilepsy.
Sorry we couldn't complete your registration. Please try again.
Please enter your email to finish creating your account.
Receive a personalized list of podcasts based on your preferences.